• Prasad Kulkarni on dengue monoclonal antibodies
    Feb 23 2024

    Prasad Kulkarni discusses a new Phase I trial in The Lancet Infectious Diseases on a dengue monoclonal antibody also known as VIS513 in healthy adults. In addition, he highlights the wider implications of this for dengue control and drug development.

    Read the full article:
    https://www.thelancet.com/journals/laninf/article/ S1473-3099(24)00030-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_laninf

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Show more Show less
    19 mins
  • Oriol Mitjà on treatment of early syphilis in adults
    Jan 8 2024

    Oriol Mitjà discusses a new trial in The Lancet Infectious Diseases on the use of oral linezolid compared with benzathine penicillin G for the treatment of early syphilis in adults. He also highlights what the trial means for treatment of syphilis.

    Read the full article:
    https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00683-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_laninf

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Show more Show less
    15 mins
  • Sofia Viegas and Stefan Niemann on emerging bedaquiline resistance in Mozambique
    Nov 10 2023

    Sofia Viegas and Stefan Niemann discuss a new article in The Lancet Infectious Diseases about emerging bedaquiline resistance in Mozambique and its implications for drug resistant tuberculosis and the fight to end tuberculosis.

    Read the full article:
    https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00498-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_laninf

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Show more Show less
    25 mins
  • Luciano Moreira and Henrik Salje on Wolbachia control of mosquito-borne infections
    Sep 27 2022

    Luciano Moreira and Henrik Salje discuss a new article in The Lancet Infectious Diseases describing the use of the Wolbachia bacteria to control the spread of mosquito-borne dengue and chikungunya in Rio de Janeiro, Brazil.

    Read the full article:
    Estimating the effect of the wMel release programme on the incidence of dengue and chikungunya in Rio de Janeiro, Brazil

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Show more Show less
    17 mins
  • Richard Maude on malaria chemoprophylaxis in Cambodia
    Sep 27 2022

    Richard Maude discusses a new article in The Lancet Infectious Diseases that assesses the efficacy of malaria chemoprophylaxis among forest goers in Cambodia.

    Read the full article:
    Antimalarial chemoprophylaxis for forest goers in southeast Asia

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Show more Show less
    13 mins
  • Ben Cowling on COVID-19 vaccines in Hong Kong
    Jul 15 2022

    Ben Cowling discusses a new article in The Lancet Infectious Diseases describing the protection that vaccines are providing against COVID-19 in Hong Kong.

    Read the full article:
    Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Show more Show less
    21 mins
  • Hugh Adler on monkeypox in the UK
    May 26 2022

    Hugh Adler discusses a new article in The Lancet Infectious Diseases describing the management and the clinical features for seven patients with monkeypox hospitalised in the UK between 2018 and 2021.

    Read the full article:
    Clinical features and management of human monkeypox: a retrospective observational study in the UK

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Show more Show less
    18 mins
  • Beate Kampmann, Karen Keddy, and Peter Ghazal on applying big data to childhood infectious diseases in LMICs
    Dec 14 2021

    Prof Beate Kampmann, Dr Karen Keddy, and Prof Peter Ghazal discuss a new cross-journal Series in The Lancet Infectious Diseases and EBioMedicine addressing the potential for and challenge of applying big data to childhood infectious diseases in LMICs.

    Read the full Series:
    https://www.thelancet.com/series/big-data-childhood-infections-LMICs

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Show more Show less
    22 mins